Advertisement

Autoimmune Lebererkrankungen

  • H. Dancygier
Chapter

Zusammenfassung

Mit der zunehmenden Entschlüsselung immunologischer Vorgänge hat auch das Interesse an immunologisch bedingten und insbesondere an Autoimmunerkrankungen der Leber zugenommen. Diese relativ seltenen, pathogenetisch und klinisch interessanten Krankheiten vermitteln einen Eindruck der Folgen einer ungebremsten immunologischen Entzündungsreaktion für das hepatobiliäre System. Abgesehen von den wenigen Ausnahmen eines akuten Leberversagens enden alle Autoimmunerkrankungen der Leber unbehandelt in der Leberzirrhose. Je nachdem, ob der Entzündungsprozess primär das Leberparenchym oder das biliäre System betrifft, können
  • hepatitische Erkrankungen (Autoimmunhepatitis) von

  • cholestatischen Erkrankungen (primär biliäre Zirrhose, primär sklerosierende Cholangitis, autoimmune Cholangitis, biliäre Duktopenie [vanishing bile duct syndrome]) abgegrenzt werden. Eine weitere Gruppe mit überlappenden Eigenschaften wird als

  • Überlappungssyndrom bezeichnet.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Al-Khalidi JA, Czaja AJ (2001) Current concepts in the diagnosis, pathogenesis, and treatment of autoimmune hepatitis. Mayo Clin Proc 76: 1237–1252PubMedCrossRefGoogle Scholar
  2. Alvarez F, Berg PA, Bianchi FB et al. (1999) International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31: 929–938PubMedCrossRefGoogle Scholar
  3. Ben-Ari Z, Czaja AJ (2001) Autoimmune hepatitis and its variant syndromes. Gut 49: 589–594PubMedCrossRefGoogle Scholar
  4. Beuers U, Wiedmann KH, Kleber G et al. (1997) Therapie der autoimmunen Hepatitis, primär biliären Zirrhose und primär sklerosierenden Cholangitis. Konsensus der Deutschen Gesellschaft für Verdauungs-und Stoffwechselkrankheiten. Z Gastroenterol 35: 1041–1049PubMedGoogle Scholar
  5. Bogdanos DP, Choudhuri K, Vergani D (2001) Molecular mimicry and autoimmune liver disease: vituous intentions, malign consequences. Liver 21: 225–322PubMedCrossRefGoogle Scholar
  6. Clemente MG, Meloni A, Obermayer-Straub P et al. (1998) Two cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1. Gastroenterology 114: 324–328PubMedCrossRefGoogle Scholar
  7. Czaja AJ (1996) Diagnosis and therapy of autoimmune liver disease. Med Clin North Am 80: 973–994PubMedGoogle Scholar
  8. Czaja AJ (2001) Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol 96: 1224–1231PubMedCrossRefGoogle Scholar
  9. Czaja AJ, Manns MP (1995) The validity and importance of subtypes of autoimmune hepatitis: a point of view. Am J Gastroenterol 90: 1206–1211PubMedGoogle Scholar
  10. Czaja AJ, Carpenter HA (1996) Validation of a scoring system for the diagnosis of autoimmune hepatitis. Dig Dis Sci 41: 305–314PubMedCrossRefGoogle Scholar
  11. Czaja AJ, Cassani F, Cataleta M et al. (1996) Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 24: 1068–1073PubMedCrossRefGoogle Scholar
  12. Czaja AJ, Kruger M, Sanrach PJ et al. (1997) Genetic distinctions between types 1 and 2 autoimmune hepatitis. Am J Gastroenterol 92: 2197–2200PubMedGoogle Scholar
  13. Dienes HP (2000) Autoimmune Hepatitis. In: Denk H, Dienes HP, Düllmann J et al. (Hrsg) Pathologie der Leber und Gallenwege. Springer, Berlin Heidelnerg New York, S 379–389Google Scholar
  14. Dienes HP, Popper H, Manns M et al. (1989) Histologic features in autoimmune hepatitis. Z Gastroenterol 27: 325–330PubMedGoogle Scholar
  15. Doherty DG, Donaldson PT, Underhill JA et al. (1994) Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 19: 609–615PubMedCrossRefGoogle Scholar
  16. Gerotto M, Pontisso P, Giostra F et al. (1994) Analysis of the hepatitis C virus genome in patients with anti-LKM-1 autoantibodies. J Hepatol 21: 273–276PubMedCrossRefGoogle Scholar
  17. Gish RG, Mason A (2001) Autoimmune liver disease: current standards, future directions. Clin Liver Dis 5: 287–314PubMedCrossRefGoogle Scholar
  18. Johnson PJ, McFarlane IG (1993) Meeting report of the International Autoimmune Hepatitis Group. Hepatology 18: 998–1005PubMedCrossRefGoogle Scholar
  19. Johnson PJ, McFarlane IG, Williams R (1995) Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 333: 958–963PubMedCrossRefGoogle Scholar
  20. Kanzler S, Weidemann C, Gerken G et al. (1999) Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol 31: 635–640PubMedCrossRefGoogle Scholar
  21. Kernebeck T, Lohse AW, Grotzinger J (2001) A Biolnformatical approach suggests the function of the autoimmune hepatitis target antigen soluble liver antigen/liver pancreas. Hepatology 34: 230–233PubMedCrossRefGoogle Scholar
  22. Leuschner U (2001) Autoimmunkrankheiten der Leber und Overlapsyndrome. Uni-Med Verlag, BremenGoogle Scholar
  23. Lohr H, Manns MP, Kyriatsoulis A et al. (1991) Clonal analysis of liver-infiltrating T cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis. Clin Exp Immunol 84: 297–302PubMedCrossRefGoogle Scholar
  24. Manns MP, Griffin KJ, Sullivan KF et al. (1991) LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 mono oxygenase. J Clin Invest 88: 1370–1378PubMedCrossRefGoogle Scholar
  25. Manns MP, Strassburg CP (2001) Autoimmune hepatitis: clinical challenges. Gastroenterology 120: 1502–1517PubMedCrossRefGoogle Scholar
  26. McFarlane IG (1999) Pathogenesis of autoimmune hepatitis. Biomed Pharmacother 53: 255–263PubMedCrossRefGoogle Scholar
  27. Michitaka K, Durazzo M, Tillmann HL et al. (1994) Analysis of hepatitis C virus genome in patients with autoimmune hepatitis type 2. Gastroenterology 106: 1603–1610PubMedGoogle Scholar
  28. Muratori L, Parola M, Ripalti A et al. (2000) Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut 46: 553–561PubMedCrossRefGoogle Scholar
  29. Neuberger J, Portmann B, Calne R et al. (1984) Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting. Transplantation 37: 363–365PubMedCrossRefGoogle Scholar
  30. Pratt DS, Flavin DP, Kaplan MM (1996) The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology 110: 271–274PubMedCrossRefGoogle Scholar
  31. Pratt DS, Fawaz KA, Rabson A et al. (1997) A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroeneterology 113: 664–668CrossRefGoogle Scholar
  32. Roberts SK, Therneau TM, Czaja AJ (1996) Prognosis of his tological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 110: 848–857PubMedCrossRefGoogle Scholar
  33. Sanchez-Urdazpal L, Czaja AJ, van Hoek B et al. (1992) Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 15: 215–221PubMedCrossRefGoogle Scholar
  34. Schalm SW, Summerskill WHJ, Go VLW (1977) Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone. Gastroenterology 72: 910–913PubMedGoogle Scholar
  35. Summerskill WHJ (1974) Chronic active liver disease reexamined: prognosis hopeful. Gastroenterology 66: 450–464PubMedGoogle Scholar
  36. Summerskill WHJ, Korman MG, Ammon HV et al. (1975) Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 16: 876–883PubMedCrossRefGoogle Scholar
  37. Te HS, Koukoulis G, Granger DR (1997) Autoimmune hepatitis: a histological variant associated with prominent centrilobular necrosis. Gut 41: 269–271PubMedCrossRefGoogle Scholar
  38. Vogel A, Liermann H, Harms A et al. (2001) Autoimmune regulator AIRE: evidence for genetic differences between autoimmune hepatitis and hepatitis as part of the autoimmune polyglandular syndrome type 1. Hepatology 33: 1047–1052PubMedCrossRefGoogle Scholar
  39. Volkmann M, Martin L, Bäurle A et al. (2001) Suluble liver antigen: isolation of a 35-kd recombinant protein (SLA-p35) specifically recognizing sera from patients with autoimmune hepatitis. Hepatology 33: 591–596PubMedCrossRefGoogle Scholar
  40. Wesierska-Gadek J, Grimm R, Hitchman E et al. (1998) Members of the glutathione S-transferase gene family are antigens in autoimmune hepatitis. Gastroenterology 114: 329–335PubMedCrossRefGoogle Scholar
  41. Wies I, Brunner S, Henninger J et al. (2000) Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 355: 1510–1515PubMedCrossRefGoogle Scholar
  42. Yamamoto AM, Cresteil D, Homberg JC et al. (1993) Characterization of the anti-liver-kidney microsomoe antibody (anti-LKM1) from hepatitis C virus-positive and-negative sera. Gastroenterology 104: 1762–1767PubMedGoogle Scholar
  43. Zauli D, Ghetti S, Grassi A et al. (1997) Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology 25: 1105–1107PubMedCrossRefGoogle Scholar
  44. Angulo P, Batts KP, Therneau TM et al. (1999) Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 29: 644–647PubMedCrossRefGoogle Scholar
  45. Angulo P, Lindor KD (1999) Primary biliary cirrhosis and primary sclerosing cholangitis. Clin Liver Dis 3: 529–570PubMedCrossRefGoogle Scholar
  46. Angulo P, Jorgensen RA, Keach JC et al. (2000) Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 31: 318–323PubMedCrossRefGoogle Scholar
  47. Bach N, Thung SN, Schaffner F (1998) The histologic effects of low-dose methotrexate therapy for primary biliary cirrhosis. Arch Pathol Lab Med 122: 342–345PubMedGoogle Scholar
  48. Christensen E, Neuberger J, Crowe J et al. (1985) Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis: final results of an international trial. Gastroenterology 89: 1084–1091PubMedGoogle Scholar
  49. Combes B, Markin RS, Wheeler DE et al. (1999) The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis. Hepatology 30: 602–605PubMedCrossRefGoogle Scholar
  50. Corpechot C, Carrat F, Bonnand AM et al. (2000) The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 32: 1196–1199PubMedCrossRefGoogle Scholar
  51. Davern TJ, Lake JR (1998) Recurrent disease after liver transplantation. Semin Gastrointest Dis 9: 86–109PubMedGoogle Scholar
  52. Dickson E, Grambsch PM, Fleming TR et al. (1989) Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 10: 1–7PubMedCrossRefGoogle Scholar
  53. Galperin C, Gershwin ME (1996) Immunopathology of primary biliary cirrhosis. Bailliere’s Clin Gastroenterol 10: 461–481CrossRefGoogle Scholar
  54. Goulis J, Leandro G, Burroughs AK (1999) Randomised controlled trials of ursodeoxycholic acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 354: 1053–1060PubMedCrossRefGoogle Scholar
  55. Heathcote EJ (1999) Evidence-based therapy of primary biliary cirrhosis. Eur J Gastroenterol Hepatol 11: 607–615PubMedCrossRefGoogle Scholar
  56. Heathcote EJ (2000) Management of primary biliary cirrhosis. Hepatology 31: 1005–1013PubMedCrossRefGoogle Scholar
  57. Hendrickse M, Rigney E, Giaffer MH et al. (1999) Low-dose methotrexate in primary biliary cirrhosis: long-term results of a placebo controlled trial. Gastroenterology 117: 400–407PubMedCrossRefGoogle Scholar
  58. Hodgson SF, Dickson ER, Wahner HW et al. (1985) Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med 103: 855–860PubMedGoogle Scholar
  59. Invernizzi P, Podda M, Battezzati PM et al. (2001) Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol 34: 366–372PubMedCrossRefGoogle Scholar
  60. James OFW, Bhopal R, Howel D et al. (1999) Primary biliary cirrhosis once rare, now common in the United Kingdom? Hepatology 30: 390–394PubMedCrossRefGoogle Scholar
  61. Jones DEJ, Metcalf JV, Collier JD et al. (1997) Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology 26: 1138–1142PubMedCrossRefGoogle Scholar
  62. Kaplan MM (1996) Primary biliary cirrhosis. N Engl J Med 335: 1570–1580PubMedCrossRefGoogle Scholar
  63. Kim WR, Wiesner RH, Therneau TM et al. (1998) Optimal timing of liver transplantation for primary biliary cirrhosis. Hepatology 28: 33–38PubMedCrossRefGoogle Scholar
  64. Kim WR, Lindor KD, Locke III GR et al. (2000) Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 119: 1631–1636PubMedCrossRefGoogle Scholar
  65. Kingham JG, Parker DR (1998) The association between primary biliary cirrhosis and coeliac disease: a study of relative prevalences. Gut 42: 120–122PubMedCrossRefGoogle Scholar
  66. Krzeski P, Zych W, Kraszewska E et al. (1999) Is serum bilirubin concentration the only valid prognostic marker in primary biliary cirrhosis? Hepatology 30: 865–869PubMedCrossRefGoogle Scholar
  67. Leuschner U, Güldütüna S, Imhof M et al. (1994) Effect of ursodeoxycholic acid after 4 to 12 years of therapy in early and late stages of primary biliary cirrhosis. J Hepatol 21: 624–633PubMedCrossRefGoogle Scholar
  68. Leuschner M, Güldütüna S, You T et al. (1996) Ursodeoxycholie acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis. J Hepatol 25: 49–57PubMedCrossRefGoogle Scholar
  69. Leuschner M, Maier KP, Schlichting J et al. (1999) Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhois: results of a prospective double blind trial. Gastroenterology 117: 918–925PubMedCrossRefGoogle Scholar
  70. Leuschner M, Dietrich CF, You T et al. (2000) Characterization of patients with primary biliary cirrhosis responding to long-term ursodeoxycholic acid therapy. Gut 46: 121–126PubMedCrossRefGoogle Scholar
  71. Lindor KD, Dickson ER, Jorgensen RA et al. (1995) The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study. Hepatology 22: 1158–1162PubMedGoogle Scholar
  72. Lindor KD, Hoofnagle J, Maddrey WC et al. (1996) Primary biliary cirrhosis clinical research single-topic conference. Hepatology 23: 639–644PubMedCrossRefGoogle Scholar
  73. Lindor KD, Therneau TM, Jorgensen RA et al. (1996) Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 110: 1515–1518PubMedCrossRefGoogle Scholar
  74. Lombard M, Portmann B, Neuberger J (1993) Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology 104: 519–526PubMedGoogle Scholar
  75. Ludwig J, Dickson ER, McDonald GS (1978) Staging of non-suppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 379: 103–112PubMedCrossRefGoogle Scholar
  76. Mason AL, Xu L, Guo L et al. (1998) Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet 351: 1620–1624PubMedCrossRefGoogle Scholar
  77. Metcalf JV, Mitchison HC, Palmer JM et al. (1996) Natural history of early primary biliary cirrhosis. Lancet 348: 1399–1402PubMedCrossRefGoogle Scholar
  78. Mitchison HC, Bassendine MF, Hendrick A et al. (1986) Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis? Hepatology 6: 1279–1284PubMedCrossRefGoogle Scholar
  79. Mitchison HC, Palmer JM, Bassendine MF et al. (1992) A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. J Hepatol 15: 336–344PubMedCrossRefGoogle Scholar
  80. Neuberger J, Thomson R (1999) PBC and AMA — what is the connection? Hepatology 29: 271–276PubMedCrossRefGoogle Scholar
  81. Poupon RE, Poupon R, Balkau B et al. (1994) Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 330: 1342–1347PubMedCrossRefGoogle Scholar
  82. Poupon RE, Lindor KD, Cauch-Dudek K et al. (1997) Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 113: 884–890PubMedCrossRefGoogle Scholar
  83. Poupon RE, Bonnand AM, Chretien Y et al. (1999) Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Hepatology 29: 1668–1671PubMedCrossRefGoogle Scholar
  84. Scheuer PJ (1967) Primary biliary cirrhosis. Proc R Soc Med 60: 1257–1260PubMedGoogle Scholar
  85. Shapiro JM, Smith H, Schaffner F (1979) Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut 20: 137–140PubMedCrossRefGoogle Scholar
  86. Strassburg CP, Jaeckel E, Manns MP (1999) Anti-mitochondrial antibodies and other immunological tests in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 11: 595–601PubMedCrossRefGoogle Scholar
  87. Tanaka A, Borchers AT, Ishibashi H et al. (2001) Genetic and familial considerations of primary biliary cirrhosis. Am J Gastroenterol 96: 8–15PubMedCrossRefGoogle Scholar
  88. Wolfbagen FHJ, van Hoogstraten HJF, van Buuren HR et al. (1998) Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study. J Hepatol 29: 736–742CrossRefGoogle Scholar
  89. Xu L, Guo L, Joplin R et al. (1997) Viral induction of primary biliary cirrhosis. J Hepatol 2: 61Google Scholar
  90. Xu L, Guo L, Keogh A et al. (2000) Isolation and characterization of a novel virus associated with primary biliary cirrhosis. Hepatology 32: 297 ACrossRefGoogle Scholar
  91. Yamazaki A, Suzuki K, Nakamura A et al. (1999) Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis. Hepatology 30: 71–78PubMedCrossRefGoogle Scholar
  92. Ben-Ari Z, Dhillon AP, Sherlock S (1993) Autoimmune cholangiopathy: part of the spectrum of chronic active hepatitis. Hepatology 18: 10–15PubMedCrossRefGoogle Scholar
  93. Brunner G, Klinge O (1987) Ein der chronisch-destruierenden nichteitrigen Cholangitis ähnliches Krankheitsbild mit antinukleären Antikörpern (Immuncholangitis). Dtsch Med Wochenscher 112: 1454–1458CrossRefGoogle Scholar
  94. Carrougher JG, Shaffer RT, Canales LI et al. (1991) A 33-year old woman with an autoimmune syndrome. Semin Liver Dis 11: 256–262PubMedCrossRefGoogle Scholar
  95. Colombato LA, Alvarez F, Cote J et al. (1994) Autoimmune cholangiopathy: the result of consecutive primary biliary cirrhosis and autoimmune hepatitis? Gastroenterology 107: 1839–1843PubMedGoogle Scholar
  96. Czaja AJ, Carpenter HA, Santrach PJ et al. (2000) Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 31: 1231–1238PubMedCrossRefGoogle Scholar
  97. Goodman ZD, McNally PR, Davis DR et al. (1995) Autoimmune cholangitis: a variant of primary biliary cirrhosis. Clinicopathologic and serologic considerations in 200 cases. Dig Dis Sci 40: 1232–1242PubMedCrossRefGoogle Scholar
  98. Heathcote J (1997) Autoimmune cholangitis. Gut 40: 440–442PubMedGoogle Scholar
  99. Invernizzi P, Crosignani A, Battezzati PM et al. (1997) Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and-negative primary biliary cirrhosis. Hepatology 25: 1090–1095PubMedCrossRefGoogle Scholar
  100. Kinoshita H, Omagari K, Whittingham S et al. (1999) Autoimmune cholangitis and primary biliary cirrhosis — an autoimmune enigma. Liver 19: 122–128PubMedCrossRefGoogle Scholar
  101. Kitami N, Komada T, Ishii H (1995) Immunological study of anti-M2 in mitochondrial antibody negative primary biliary cirrhosis. Intern Med 34: 496–501PubMedCrossRefGoogle Scholar
  102. Lacerda MA, Ludwig J, Dickson ER et al. (1995) Antimitochondrial antibody-negative primary biliary cirrhosis. Am J Gastroenterol 90: 247–249PubMedGoogle Scholar
  103. Mohr L, Heintges T, Hensel F et al. (1998) Treatment of autoimmune cholangitis. Dis Dis Sci 43: 2160–2163CrossRefGoogle Scholar
  104. Michieletti P, Wanless IR, Katz et al. (1994) Antimitochondrial negative primary biliary cirrhosis: a distinct clinical syndrome of autoimmune cholangitis. Gut 35: 260–265PubMedCrossRefGoogle Scholar
  105. Nakanuma Y, Harada K, Kaji K et al. (1997) Clinicopathological study of primary biliary cirrhosis negative for antimitochondrial antibodies. Liver 17: 281–287PubMedGoogle Scholar
  106. Sherlock S (1998) Autoimmune cholangitis. A unique entity? Mayo Clin Proc 73: 184–190PubMedCrossRefGoogle Scholar
  107. Taylor SL, Dean PJ, Rieley CA (1994) Primary autoimmune cholangitis: an alternative to antimitochondrial antibodynegative primary biliary cirrhosis. Am J Surg Pathol 18: 91–99PubMedCrossRefGoogle Scholar
  108. Angulo P, Lindor KD (1999) Primary sclerosing cholangitis. Hepatology 30: 325–332PubMedCrossRefGoogle Scholar
  109. Baron TH, Koehler RE, Rodgers WH et al. (1995) Mast cell cholangiopathy: another cause of sclerosing cholangitis. Gastroenterology 109: 1677–1681PubMedCrossRefGoogle Scholar
  110. Bass NM, Chapman RW, O’Reilly A et al. (1983) Primary sclerosing cholangitis associated with angioimmunoblastic lymphadenopathy. Gastroenterology 85: 420–424Google Scholar
  111. Dienes HP, Lohse AW, Gerken G et al. (1997) Bile duct epithelia as target cells in primary biliary cirrhosis and primary sclerosing cholangitis. Virchows Arch 431: 119–124PubMedCrossRefGoogle Scholar
  112. Lindor KD (1997) Ursodiol for primary sclerosing cholangitis. N Engl J Med 336: 691–695PubMedCrossRefGoogle Scholar
  113. Ludwig J (1991) Small-duct primary sclerosing cholangitis. Semin Liver Dis 11: 11–17PubMedCrossRefGoogle Scholar
  114. Ludwig J, Barham SS, LaRusso NF et al. (1981) Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1: 632–640PubMedCrossRefGoogle Scholar
  115. Mitchell SA, Bansi DS, Hunt N et al. (2001) A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 121: 900–907PubMedCrossRefGoogle Scholar
  116. Ponsioen CIJ, Tytgat GNJ (1998) Primary sclrosing cholangitis: a clinical review. Am J Gastroenterol 93: 515–523PubMedCrossRefGoogle Scholar
  117. Ponsioen CIJ, Vrouenraets SME, van Milligen de Wit AWM et al. (1999) Value of brush cytology for dominant strictures in primary sclerosing cholangitis. Endoscopy 31: 305–309PubMedCrossRefGoogle Scholar
  118. Ramos FJ, Perez-Arellano JI, Lopez-Borrasca A (1987) Primary sclerosing cholangitis in histiocytosis X. Am J Med 82: 191PubMedCrossRefGoogle Scholar
  119. Rösch T, Dancygier H (1988) Primär sklerosierende Cholangitis. Leber Magen Darm 18: 184–196PubMedGoogle Scholar
  120. Stiehl A, Rudolph G, Sauer P et al. (1997) Efficacy of ursodeoxycholic acid treatment and endoscopic dilatation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study. J Hepatol 26: 560–566PubMedCrossRefGoogle Scholar
  121. Wiesner RH, Grambsch PM, Dickson ER et al. (1989) Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 10: 430–436PubMedCrossRefGoogle Scholar
  122. Desmet VJ (1997) Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol 26 [suppl 1]: 31–35PubMedCrossRefGoogle Scholar
  123. Garda-Jimenez ME, Quiroga JA, Gutierrez ML et al. (2001) Association of HLA-DR genes with mild idiopathic adulthood ductopenia. Am J Gastroenterol 96: 1178–1182Google Scholar
  124. Hübscher SG (1999) Pathology of vanishing bile duct syndromes. In: Neuberger J (ed) Primary biliary cirrhosis. West End Studios Ltd, UK, pp 41–52Google Scholar
  125. Ludwig J (1998) Idiopathic adulthood ductopenia: an update. Mayo Clin Proc 73: 285–291PubMedCrossRefGoogle Scholar
  126. Ludwig J, Wiesner RH, LaRusso NF (1988) Idiopathic adulthood ductopenia: a cause of chronic cholestatic liver disease and biliary cirrhosis. J Hepatol 7: 193–199PubMedCrossRefGoogle Scholar
  127. Moreno A, Carreno V, Cano A (1997) Idiopathic biliary ductopenia in adults without symptoms of liver disease. N Engl J Med 336: 835–838PubMedCrossRefGoogle Scholar
  128. Müller C, Ulrich W, Penner E (1995) Manifestation late in life of idiopathic adulthood ductopenia. Liver 15: 213–218PubMedGoogle Scholar
  129. Woolf GM, Vierling JM (1993) Disappearing intrahepatic bile ducts: the syndromes and their mechanisms. Semin Liver Dis 13: 261–275PubMedCrossRefGoogle Scholar
  130. Zafrani ES, Metreau JM, Douvin C et al. (1990) Idiopathic biliary ductopenia in adults: a report of five cases. Gastroenterology 99: 1823–1828PubMedGoogle Scholar
  131. Ben Ari Z, Dhillon AP, Sherlock S (1993) Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis. Hepatology 18: 10–15CrossRefGoogle Scholar
  132. Ben Ari Z, Czaja AT (2001) Autoimmune hepatitis and its variant syndromes. Gut 49: 589–594CrossRefGoogle Scholar
  133. Boberg KM, Fausa O, Haaland T et al. (1996) Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 23: 1369–1376PubMedCrossRefGoogle Scholar
  134. Chazouillieres O (2000) Diagnosis of primary sclerosing cholangitis — autoimmune hepatitis overlap syndrome; to score or not to score? J Hepatol 33; 661–663CrossRefGoogle Scholar
  135. Chazouillieres O, Wendum D, Serfaty L et al. (1998) Primary biliary cirrhosis — autoimmune hepatitis overlap syndrome; clinical features and response to therapy. Hepatology 28: 296–301CrossRefGoogle Scholar
  136. Czaja AJ (1996) The variant forms of autoimmune hepatitis. Ann Intern Med 125; 588–598PubMedGoogle Scholar
  137. Czaja AJ (1998) Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 28: 360–365PubMedCrossRefGoogle Scholar
  138. Gohlke F, Lohse AW, Dienes HP et al. (1996) Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J Hepatol 24; 699–705PubMedCrossRefGoogle Scholar
  139. Kanzler S, Bozkurt S, Herkel J et al. (2001) Nachweis von SLAI LP-Autoantikörpern bei Patienten mit primär biliärer Zirrhose als Marker für eine sekundäre autoimmune Hepatitis (Overlapsyndrom). Dtsch Med Wochenschr 126: 450–456PubMedCrossRefGoogle Scholar
  140. Kaserer K, Exner M, Mosberger I et al. (1998) Characterization of the inflammatory infiltrate in autoimmune cholangitis. A morphological and immunohistochemical study. Virchows Arch 432: 217–222PubMedCrossRefGoogle Scholar
  141. Kaya M, Angulo P, Lindor KD (2000) Overlap of autoimmune hepatitis and primary sclerosing cholangitis; an evaluation of a modified scoring system. J Hepatol 33: 537–542PubMedCrossRefGoogle Scholar
  142. Kim WR, Ludwig J, Lindor KD (2000) Variant forms of cholestatic diseases involving small bile ducts in adults. Am J Gastroenterol 95: 1130–1138PubMedCrossRefGoogle Scholar
  143. Lohse AW, Meyer zum Büschenfelde KH, Franz B et al. (1999) Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis; evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 29: 1978–1984CrossRefGoogle Scholar
  144. Michieletti P, Wanless IR, Katz A et al. (1994) Antimitochondrial antibody negative primary biliary cirrhosis; a distinct syndrome of autoimmune cholangitis. Gut 35: 260–265PubMedCrossRefGoogle Scholar
  145. Rubel LR, Seeff LB, Patel V (1984) Primary biliary cirrhosisprimary sclerosing cholangitis overlap syndrome. Arch Pathol Lab Med 108: 360–361PubMedGoogle Scholar
  146. Van Buuren HR, van Hoogstraten HJF, Terkivatan T et al. (2000) High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol 33: 543–548PubMedCrossRefGoogle Scholar
  147. Woodward J, Neuberger J (2001) Autoimmune overlap syndromes. Hepatology 33: 994–1002PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • H. Dancygier

There are no affiliations available

Personalised recommendations